Skip to main content
SpringerLink
Log in

Treatment of Pulmonary Tuberculosis

  • Chapter
  • First Online:
Handbook of Tuberculosis

Abstract

This chapter addresses the treatment of pulmonary tuberculosis highlighting drug classes, recommended regimens, adverse drug reactions, drug-drug interactions, and practical aspects of monitoring, The principles of treatment of latent tuberculosis are also addressed including whom to treat, what regimens to use, and practical aspects of monitoring.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946–1986, with relevant subsequent publications. Int J Tuberc Lung Dis. 1999;3(10 Suppl 2):S231–79.

    CAS  PubMed  Google Scholar 

  2. Iseman MD. A clinician’s guide to tuberculosis. Philadelphia: Lippincott Williams & Wilkins; 2000.

    Google Scholar 

  3. Treatment of tuberculosis: guidelines – 4th ed. Geneva, World Health Organization, 2010 (WHO/HTM/TB/2009.420).

    Google Scholar 

  4. Zumla A, Nahid P, Cole ST. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov. 2013;12(5):388–404.

    Article  CAS  PubMed  Google Scholar 

  5. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167(4):603–62.

    Article  PubMed  Google Scholar 

  6. Benator D, Bhattacharya M, Bozeman L, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet. 2002;360(9332):528–34.

    Article  PubMed  Google Scholar 

  7. Jo KW, Yoo JW, Hong Y, et al. Risk factors for 1-year relapse of pulmonary tuberculosis treated with a 6-month daily regimen. Respir Med. 2014;108(4):654–9.

    Article  PubMed  Google Scholar 

  8. Lee CH, Wang WJ, Lan RS, Tsai YH, Chiang YC. Corticosteroids in the treatment of tuberculous pleurisy. A double-blind, placebo-controlled, randomized study. Chest. 1988;94(6):1256–9.

    Article  CAS  PubMed  Google Scholar 

  9. Galarza I, Canete C, Granados A, Estopa R, Manresa F. Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax. 1995;50(12):1305–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Wyser C, Walzl G, Smedema JP, Swart F, van Schalkwyk EM, van de Wal BW. Corticosteroids in the treatment of tuberculous pleurisy. A double-blind, placebo-controlled, randomized study. Chest. 1996;110(2):333–8.

    Article  CAS  PubMed  Google Scholar 

  11. Elliott AM, Luzze H, Quigley MA, et al. A randomized, double-blind, placebo-controlled trial of the use of prednisolone as an adjunct to treatment in HIV-1-associated pleural tuberculosis. J Infect Dis. 2004;190(5):869–78.

    Article  CAS  PubMed  Google Scholar 

  12. Mayosi BM, Ntsekhe M, Bosch J, et al. Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med. 2014;371:1121–30.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med. 2004;351(17):1741–51.

    Article  CAS  PubMed  Google Scholar 

  14. Prasad K, Singh MB. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev. 2008;1, CD002244.

    Google Scholar 

  15. Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs. 2014;74(8):839–54.

    Article  CAS  PubMed  Google Scholar 

  16. van Rie A, Warren R, Richardson M, et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med. 1999;341(16):1174–9.

    Article  PubMed  Google Scholar 

  17. Deciding when to treat latent TB infection. Available at http://www.cdc.gov/tb/topic/treatment/decideltbi.htm. Accessed 14 June 2016.

  18. No authors listed. Targeted tuberculin testing and treatment of latent tuberculosis infection. Joint statement of the American Thoracic Society, and the Centers for Disease Control and Prevention. Am J Respir Crit Care Med. 2000;161(4 Pt 2):S221–47.

    Google Scholar 

  19. Getahun H, Matteelli A, Abubakar I, Abdel Aziz M, Baddeley A, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015;46:1563–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. World Health Organization. Guidelines on the management of latent tuberculosis infection. Geneva: World Health Organization; 2015 (WHO/HTM/TB/2015/01).

    Google Scholar 

  21. World Health Organization. Recommendations on 36 months isoniazid preventive therapy to adults and adolescents living with HIV in resource-constrained and high TB and HIV-prevalence settings: 2015 update. Geneva: World Health Organization; 2015 (WHO/HTM/TB/2015.15).

    Google Scholar 

  22. Centers for Disease Control and Prevention (CDC). Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2011;60:1650–3.

    Google Scholar 

  23. Treatment regimens for latent TB infection (LTBI). Available at http://www.cdc.gov/tb/topic/treatment/ltbi.htm. Accessed 14 June 2016.

  24. Horsburgh Jr CR, Rubin EJ. Latent tuberculosis infection in the United States. N Engl J Med. 2011;364:1441–8.

    Article  CAS  PubMed  Google Scholar 

  25. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010;1, CD000171.

    Google Scholar 

  26. Centers for Disease Control and Prevention (CDC); American Thoracic Society. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection – United States, 2003. MMWR Morb Mortal Wkly Rep. 2003;52:735–9.

    Google Scholar 

  27. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365:2155–66.

    Article  CAS  PubMed  Google Scholar 

  28. Villarino ME, et al. Treatment for preventing tuberculosis in children and adolescents. JAMA Pediatr. 2015;169(3):247–55.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Johns Hopkins University School of Medicine, 1550 Orleans St, Rm 1M-12, Baltimore, MD, 21231, USA

    Susan Dorman

  2. Center for Clinical Global Health Education, Johns Hopkins University, 600 North Wolfe Street, Phipps 540B, Baltimore, MD, 21287, USA

    Amita Gupta

Authors
  1. Susan Dorman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amita Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susan Dorman .

Editor information

Editors and Affiliations

  1. Johns Hopkins Center for TB Research, Baltimore, Maryland, USA

    Jacques H. Grosset

  2. Johns Hopkins Center for TB Research, Baltimore, Maryland, USA

    Richard E. Chaisson

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Dorman, S., Gupta, A. (2017). Treatment of Pulmonary Tuberculosis. In: Grosset, J., Chaisson, R. (eds) Handbook of Tuberculosis. Adis, Cham. https://doi.org/10.1007/978-3-319-26273-4_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-26273-4_3

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-26271-0

  • Online ISBN: 978-3-319-26273-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation